In cryoimmunotherapy, target tumors are treated with cryoablation to generate antitumor immune responses. Because immune checkpoint inhibitors have demonstrated that lung cancer can be an immunotherapy-responsive disease, there has been renewed interest in the immunological aspects of cryoablation of lung cancer. Herein, we review preclinical and clinical trials of cryoablation of primary lung tumors. We examine the magnitude of cryoablation-induced antitumor immune responses and the synergy between cryoablation and either other immunotherapies or molecular targeted therapies to improve treatment responses in advanced lung cancer. We further discuss a rationale for the addition of cryoablation to immune checkpoint inhibitors for the treatment of advanced lung cancer, which is currently under clinical investigation.

中文翻译：

---

非小细胞肺癌冷冻消融的免疫学方面：综合综述

在冷冻免疫疗法中，通过冷冻消融治疗靶肿瘤以产生抗肿瘤免疫反应。由于免疫检查点抑制剂已经证明肺癌可以是一种免疫治疗反应性疾病，因此人们对肺癌冷冻消融的免疫学方面重新产生了兴趣。在此，我们回顾了原发性肺肿瘤冷冻消融的临床前和临床试验。我们检查了冷冻消融诱导的抗肿瘤免疫反应的程度，以及冷冻消融与其他免疫疗法或分子靶向疗法之间的协同作用，以改善晚期肺癌的治疗反应。我们进一步讨论了在免疫检查点抑制剂中加入冷冻消融治疗晚期肺癌的基本原理，目前正在进行临床研究。